+

WO2004047860A3 - Cellules non presentatrices d'antigene pour supprimer des reactions immunitaires pathologiques - Google Patents

Cellules non presentatrices d'antigene pour supprimer des reactions immunitaires pathologiques Download PDF

Info

Publication number
WO2004047860A3
WO2004047860A3 PCT/EP2003/013402 EP0313402W WO2004047860A3 WO 2004047860 A3 WO2004047860 A3 WO 2004047860A3 EP 0313402 W EP0313402 W EP 0313402W WO 2004047860 A3 WO2004047860 A3 WO 2004047860A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
immune reactions
pathological immune
presenting antigen
suppressing pathological
Prior art date
Application number
PCT/EP2003/013402
Other languages
German (de)
English (en)
Other versions
WO2004047860A2 (fr
Inventor
Ahmed Sheriff
Birgit Vogt
Original Assignee
Genethor Gmbh
Ahmed Sheriff
Birgit Vogt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethor Gmbh, Ahmed Sheriff, Birgit Vogt filed Critical Genethor Gmbh
Priority to AU2003289907A priority Critical patent/AU2003289907A1/en
Publication of WO2004047860A2 publication Critical patent/WO2004047860A2/fr
Publication of WO2004047860A3 publication Critical patent/WO2004047860A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de cellules non présentatrices d'antigène qui sont transfectées avec le transactivateur de classe II (CIITA) pour la sélection in vivo de lymphocytes T.
PCT/EP2003/013402 2002-11-28 2003-11-28 Cellules non presentatrices d'antigene pour supprimer des reactions immunitaires pathologiques WO2004047860A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003289907A AU2003289907A1 (en) 2002-11-28 2003-11-28 Cells not presenting antigen for suppressing pathological immune reactions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026582 2002-11-28
EP02026582.3 2002-11-28

Publications (2)

Publication Number Publication Date
WO2004047860A2 WO2004047860A2 (fr) 2004-06-10
WO2004047860A3 true WO2004047860A3 (fr) 2004-08-05

Family

ID=32338007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013402 WO2004047860A2 (fr) 2002-11-28 2003-11-28 Cellules non presentatrices d'antigene pour supprimer des reactions immunitaires pathologiques

Country Status (2)

Country Link
AU (1) AU2003289907A1 (fr)
WO (1) WO2004047860A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648836A1 (fr) * 1993-08-26 1995-04-19 Bernard François Prof. Mach Transactivateur du complexe majeur d'histomcompatibilité de la classe II et ses utilisations
WO1998015626A2 (fr) * 1996-10-08 1998-04-16 Institute Of Child Health Molecule mutante ciita et ses utilisations
WO2001032189A1 (fr) * 1999-10-26 2001-05-10 Osiris Therapeutics, Inc. Surnageant issu de cellules souches mesenchymateuses pour la prevention et le traitement de reponses immunitaires lors de greffes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648836A1 (fr) * 1993-08-26 1995-04-19 Bernard François Prof. Mach Transactivateur du complexe majeur d'histomcompatibilité de la classe II et ses utilisations
WO1998015626A2 (fr) * 1996-10-08 1998-04-16 Institute Of Child Health Molecule mutante ciita et ses utilisations
WO2001032189A1 (fr) * 1999-10-26 2001-05-10 Osiris Therapeutics, Inc. Surnageant issu de cellules souches mesenchymateuses pour la prevention et le traitement de reponses immunitaires lors de greffes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARMSTRONG T D ET AL: "Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, no. 13, June 1997 (1997-06-01), pages 6886 - 6891, XP002224817, ISSN: 0027-8424 *
DATABASE EMBL 1 October 1993 (1993-10-01), "MHC class II transactivator (CIITA).", XP002278858, retrieved from EBI Database accession no. P33076 *
STEIMLE V ET AL: "REGULATION OF MHC CLASS II EXPRESSION BY INTERFERON-GAMMA MEDIATED BY THE TRANSACTIVATOR GENE CIITA", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 265, no. 5168, 1 July 1994 (1994-07-01), pages 106 - 109, XP002051563, ISSN: 0036-8075 *
YUN S ET AL: "Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain.", TRANSPLANTATION. UNITED STATES 15 JUL 1998, vol. 66, no. 1, 15 July 1998 (1998-07-15), pages 103 - 111, XP009010712, ISSN: 0041-1337 *

Also Published As

Publication number Publication date
WO2004047860A2 (fr) 2004-06-10
AU2003289907A8 (en) 2004-06-18
AU2003289907A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
AU3878697A (en) Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors
AU7495698A (en) Prolonged cold storage of red blood cells by oxygen removal and additive usage
AU3182999A (en) Methods of diagnosis and triage using cell activation measures
AU2003277183A1 (en) Improved diagnostic fluorescence and reflectance
EP1985632A3 (fr) Utilisation d'anticorps du VEGF2 pour inhiber la prolifération de cellules photoréceptrices
AU2003214604A1 (en) Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
AU2003207415A1 (en) Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
AU2003279229A1 (en) Fuel cell assembly and method of making the same
AU2003281336A1 (en) Compositions and methods for the detection of human t cell receptor variable family gene expression
AU2003231164A1 (en) Direct methanol fuel cell and system
AU7158398A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
GB2420219C (en) Fuel cells and fuel cell catalysts
IL199414A0 (en) Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents
AU2003210468A1 (en) Integrated fuel cell and electrochemical power system employing the same
AU2002246422A1 (en) Cell culture plate and system using the same
AU2003299661A1 (en) Fuel cell assemblies and methods of making the same
AU2002353075A1 (en) Multiple plateau battery charging method and system to fully charge the first plateau
AU2003302228A1 (en) Fuel cell gasket
AU2003228984A1 (en) Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
AU2003272598A1 (en) Th1 cell adoptive immunotherapy
AU6930200A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
WO2004047860A3 (fr) Cellules non presentatrices d'antigene pour supprimer des reactions immunitaires pathologiques
GB2370572B (en) Use of a professional antigen presenting cell
AU2003280736A1 (en) Catalyst for fuel cell and electrode using the same
AU2003223500A1 (en) Fuel cell

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载